ZyVersa Therapeutics, Inc. Warrants
ZVSAW
ZVSAW was delisted on the 20th of December, 2022.
0 hedge funds and large institutions have $0 invested in ZyVersa Therapeutics, Inc. Warrants in 2024 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $105 → $0 (-$105)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$105 |
ZVSAW Hedge Fund Activity: Q3 2024 in Review
0 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics, Inc. Warrants (ZVSAW) for Q3 2024, worth a combined $0 — down 100% from $105 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ZVSAW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Ancora Advisors, exiting entirely with an estimated $105 sold.
- 0 institutional investors held ZyVersa Therapeutics, Inc. Warrants (ZVSAW) as of Q3 2024, down from 1 in Q2 2024.
- Funds reported $0 of ZyVersa Therapeutics, Inc. Warrants stock for Q3 2024, down 100% quarter-over-quarter.
- 0 funds opened new ZyVersa Therapeutics, Inc. Warrants positions in Q3 2024 and 1 closed out, a net change of -1 holder.
- The largest ZyVersa Therapeutics, Inc. Warrants seller in Q3 2024 was Ancora Advisors, an estimated $105 sold.
Based on aggregated 13F filings for Q3 2024.